Clinical Trials Browser

INDUSTRY × enzalutamide × 90 days × Clear all

NCT06863272 2026-03-16

IDeate-Prostate02

Phase 1/2 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT03460977 2026-03-13

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase 1 Recruiting

LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT05901649 2026-03-13

ArtemisPRO

Active not recruiting

Metastatic Hormone-sensitive Prostate Cancer

NCT03395197 2026-03-12

TALAPRO-2

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

NCT04821622 2026-03-11

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05526248 2026-03-11

ARAMON

Phase 2 Completed

28 enrolled 14 charts

Biochemically Recurrent Prostate Cancer

NCT06136624 2026-03-11

OMAHA-003

Phase 3 Recruiting

Prostate Cancer Metastatic

NCT06136650 2026-03-09

MK-5684-004

Phase 3 Recruiting

Prostatic Neoplasms

NCT04221542 2026-03-06

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

Bites and Stings, Prostatic Neoplasms

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Phase 3 Recruiting

Neoplasms, Prostatic Neoplasms

NCT07287150 2026-03-05

InavoPC

Phase 2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT06551324 2026-03-04

MEVPRO-1

Phase 3 Recruiting

Prostatic Neoplasms, Recurrence

NCT06629779 2026-03-04

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Phase 3 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT07028853 2026-03-04

MEVPRO-3

Phase 3 Recruiting

Prostatic Neoplasms

NCT07230106 2026-03-03

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT06257693 2026-02-27

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Phase 1 Recruiting

Prostate Adenocarcinoma

NCT05968599 2026-02-25

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

2,731 enrolled 14 charts

Prostatic Neoplasms, Castration-Resistant

NCT05997615 2026-02-24

AMX-500

Phase 1 Recruiting

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06855277 2026-02-24

AcTFirst

Phase 3 Recruiting

Prostatic Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT06991556 2026-02-17

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Phase 2 Recruiting

Metastatic Hormone-sensitive Prostate Cancer

NCT07226986 2026-02-17

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Phase 1/2 Recruiting

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT05818683 2026-02-13

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Phase 1 Recruiting

Metastatic Castration-resistant Prostate Neoplasms

NCT07406282 2026-02-12

Double-DARE

Prostatic Neoplasms

NCT05551117 2026-02-09

Tamarack

Phase 2 Terminated

192 enrolled 20 charts

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT04076059 2026-02-06

China ARCHES

Phase 3 Active not recruiting

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Phase 1 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT05701007 2026-01-29

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

1,083 enrolled 29 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT06764485 2026-01-28

rechARge

Phase 3 Recruiting

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02003924 2026-01-27

PROSPER

Phase 3 Completed

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

Phase 2 Completed

292 enrolled 21 charts

Prostatic Neoplasms

NCT06120491 2026-01-21

EvoPAR-PR01

Phase 3 Recruiting

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

Phase 3 Active not recruiting

455 enrolled 18 charts

Prostatic Neoplasms

NCT05112965 2026-01-07

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

Neoplasms

NCT07277270 2026-01-07

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT06072196 2025-12-31

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

3,017 enrolled 5 charts

Prostatic Neoplasms

NCT06228053 2025-12-22

SYNERGY-201

Phase 2 Recruiting

Metastatic Castration-resistant Prostate Cancer

NCT05457257 2025-12-19

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Phase 4 Completed

43 enrolled 16 charts

Metastatic Castration-resistant Prostate Cancer